Clinical trial
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT04577963
Study timeline
Study start (actual)2021-08-09Date precision: day
Registry last updated2025-07-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Endometrial Cancerunresolved
Solid Tumor, Unspecified, Adultunresolved
Colorectal Cancerunresolved
Interventions
FruquintinibDRUG · verified · RxNorm: fruquintinib
TislelizumabDRUG · verified · RxNorm: tislelizumab
Sponsors & collaborators
Mapped research locations
NashvilleTennessee, United States2HoustonTexas, United States1PhoenixArizona, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1ProvidenceRhode Island, United States1West Palm BeachFlorida, United States1Baton RougeLouisiana, United States1St. PetersburgFlorida, United States1ChattanoogaTennessee, United States1Beverly HillsCalifornia, United States1AshevilleNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04577963 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.